"HY2019 has seen Volpara continuing to mature into a major player in the US breast imaging market. Just over 5.4% of women being screened (approximately 2.1M+) are now being actively analysed by a Volpara product. By the financial year end this is forecasted
to rise to 9.0% of women, a significant level of penetration into the world’s biggest breast imaging market. Volpara, with much of its breast imaging analytics data flowing to the cloud, now has one of the biggest cross-vendor data sets in mammography, a powerful asset not only for finding key insights to help detect breast cancer early but also for developing new products that can help increase our average price per patient (ARPU)."
 Half Year Accounts 26 pages 4.0MB